Dr. Perlmutter is the Executive Vice President and President of Merck Research Laboratories. From 2001 until 2012, he was the Executive Vice President for Research and Development at Amgen. He was responsible for the registration of ten significant new drugs including Sensipar™, Prolia™ and Xgeva™. Prior to joining Amgen, Dr. Perlmutter was for many years Professor and Chairman of the Department of Immunology at the University of Washington in Seattle, and an Investigator of the Howard Hughes Medical Institute. He also served as Executive Vice President for Worldwide Discovery and Preclinical Research at Merck & Co. Dr. Perlmutter is a Fellow of the American Academy of Arts and Sciences.

Dr. Perlmutter served as a Board Director of Exonics Therapeutics until the company was acquired by Vertex in June 2019.

Board of Directors: Eikon Therapeutics (Chairman), NGM Biopharmaceuticals

Involvement: TCG I, TCG II, & TCG III